Vera Therapeutics, Inc. - Class A Common Stock - Nakit Akışı (NASDAQ:VERA) | MetaTrader

Tam grafiği aç Full chart

Financials

Genel Bakış Tablolar İstatistikler

Çeyreklik Yıllık

İşletme faaliyetlerinden elde edilen nakit -23.71 M-67.6 M-92.18 M-134.68 M-241.1 M -293.2 M Yatırım faaliyetlerinden elde edilen nakit -4.2 M-70.55 M-39.43 M-425.03 M194.29 M 41.15 M Finansman faaliyetlerinden elde edilen nakit 53.88 M101.93 M133.54 M606.67 M308.9 M 311.31 M Serbest nakit akışı -23.71 M-67.6 M-92.18 M-134.68 M-241.73 M -293.66 M

Haberler

Vera Therapeutics: Strong IgAN Data, But Differentiation Is Still Pending (NASDAQ:VERA)

Vera Therapeutics, Jane Wright-Mitchell’ı hukuk müdürü atadı

Wolfe Research, Vera Therapeutics hissesini değerleme üzerinden yükseltti

Wolfe Research upgrades Vera Therapeutics stock rating on valuation

BofA Securities, Vera Therapeutics için Al tavsiyesini yineledi

Vera Therapeutics stock rating reaffirmed at Buy by BofA Securities

Vera Therapeutics, Inc. (VERA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Vera Therapeutics adds Christopher Hite to board of directors

3 Best Stocks With 125%+ Upside Ahead, According to Top Analysts, 3/2/2026 - TipRanks.com

Vera Therapeutics: Hold Rating Based On Potential For Atacicept In IgAN (Rating Downgrade)

VeraDermics is said to draw IPO anchor order from Eli Lilly - Bloomberg

Vera Therapeutics, Matt Skelton’u ticari operasyonlar direktörü olarak terfi ettirdi